Answers are grounded in this paper and cite their sources.
Inflammatory bowel disease is a chronic inflammatory disease characterized by mucosal immunity dysregulation, epithelial barrier dysfunction, and gut microbiome dysbiosis. While cytokine-targeted therapies have improved clinical outcomes, many patients remain refractory or relapse, emphasizing the need for additional therapeutic approaches. Recent evidence suggests that mitochondrial metabolism in the intestinal epithelium regulates mucosal homeostasis, immune cell recruitment, and susceptibility to inflammation. However, it remains controversial whether mitochondrial dysfunction is a cause or a consequence of intestinal inflammation. Epithelial energetic deficiency and barrier dysfunction are associated with impaired oxidative phosphorylation, defective short-chain fatty acid utilization, redox imbalance, and faulty mitochondrial quality control. Indeed, impaired mitophagy promotes mitochondrial DNA (mtDNA) release through voltage-dependent anion channel 1 (VDAC1) oligomerization and mitochondrial permeability transition pore opening. Extracellular mtDNA acts as a damage-associated molecular pattern, activating cyclic GMP-AMP synthase-stimulator of interferon genes, toll-like receptor 9, and NLR family pyrin domain-containing 3 inflammasome pathways that amplify mucosal inflammation. These metabolic changes alter luminal oxygen and microbiome composition, whereas microbial metabolites, particularly tryptophan-derived indoles and kynurenines, modulate epithelial mitochondrial function through aryl hydrocarbon receptor signaling. These findings support a bidirectional microbiome-mitochondria-immune axis that potentiates intestinal inflammation. In this review, we summarize the current evidence of how epithelial mitochondrial dysfunction associates with intestinal inflammation. We discuss how mitochondrial metabolism interfaces with microbial ecology and immune regulation to shape disease pathogenesis. We also discuss therapeutic strategies targeting this axis: mitochondrial-targeted antioxidants (eg, MitoQ), VDAC1 inhibitors, bile-acid derivatives (eg, tauroursodeoxycholic acid), and metabolite-based therapies to restore microbial tryptophan metabolism. These approaches target mitochondrial bioenergetics and microbial metabolic cross-talk with the potential to restore microbiome-immune homeostasis, preserve barrier integrity, and complement conventional immune-directed therapies.
No takes yet. Share an insight, caveat, or question.
Torossian et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: